| scholarly article | Q13442814 |
| P356 | DOI | 10.1073/PNAS.1607931113 |
| P8608 | Fatcat ID | release_ou2nikavxfbplbf4alqrs5kyu4 |
| P3181 | OpenCitations bibliographic resource ID | 2839433 |
| P932 | PMC publication ID | 4948328 |
| P698 | PubMed publication ID | 27354515 |
| P50 | author | Lalita Priyamvada | Q55193763 |
| Jens Wrammert | Q66752613 | ||
| Srilatha Edupuganti | Q67154938 | ||
| Kovit Pattanapanyasat | Q89114397 | ||
| Kendra M Quicke | Q89930125 | ||
| Mehul S. Suthar | Q90167763 | ||
| Mark J Mulligan | Q104932176 | ||
| Rafi Ahmed | Q29017279 | ||
| P2093 | author name string | Kulkanya Chokephaibulkit | |
| Nattawat Onlamoon | |||
| Jaturong Sewatanon | |||
| Patrick C. Wilson | |||
| William H. Hudson | |||
| P2860 | cites work | Zika virus. I. Isolations and serological specificity | Q22240545 |
| Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007 | Q22241244 | ||
| Zika Virus Outbreak on Yap Island, Federated States of Micronesia | Q22250881 | ||
| Detection of Zika virus in saliva | Q22330713 | ||
| First case of Zika virus infection in a returning Canadian traveler | Q22330732 | ||
| Current Zika virus epidemiology and recent epidemics | Q22330739 | ||
| First case of laboratory-confirmed Zika virus infection imported into Europe, November 2013 | Q22330753 | ||
| Zika Virus Associated with Microcephaly | Q22683189 | ||
| Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study | Q23012849 | ||
| The 3.8 Å resolution cryo-EM structure of Zika virus | Q23680595 | ||
| Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop | Q34306877 | ||
| Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms | Q35531167 | ||
| A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus | Q35654743 | ||
| Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions | Q35982791 | ||
| A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies | Q36205859 | ||
| Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody | Q36950014 | ||
| B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts | Q36950883 | ||
| The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity | Q37448171 | ||
| Amino acid changes within the E protein hinge region that affect dengue virus type 2 infectivity and fusion | Q39585856 | ||
| Plasmablasts generated during repeated dengue infection are virus glycoprotein-specific and bind to multiple virus serotypes | Q40268140 | ||
| Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection | Q40302703 | ||
| rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults. | Q40464785 | ||
| Rapid detection and identification of dengue viruses by polymerase chain reaction (PCR). | Q40667226 | ||
| Zika Virus and Birth Defects — Reviewing the Evidence for Causality | Q23815222 | ||
| Patterns in Zika virus testing and infection, by report of symptoms and pregnancy status - United States, January 3 - March 5, 2016 | Q24261156 | ||
| Zika Virus | Q24261255 | ||
| Immunological evidence of Zika virus transmission in Thailand | Q24261420 | ||
| The global distribution and burden of dengue | Q24628768 | ||
| Dengue Virus Immunopathogenesis: Lessons Applicable to the Emergence of Zika Virus | Q27010600 | ||
| A ligand-binding pocket in the dengue virus envelope glycoprotein | Q27477685 | ||
| Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II | Q27486409 | ||
| Structure of the dengue virus envelope protein after membrane fusion | Q27643009 | ||
| Cryo-EM structure of the mature dengue virus at 3.5-Å resolution | Q27675507 | ||
| UCSF Chimera--a visualization system for exploratory research and analysis | Q27860666 | ||
| Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity | Q27860703 | ||
| Neutralization and antibody-dependent enhancement of dengue viruses | Q29618172 | ||
| Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever | Q29619530 | ||
| Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections | Q33342343 | ||
| A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein | Q33802834 | ||
| The length of and nonhydrophobic residues in the transmembrane domain of dengue virus envelope protein are critical for its retention and assembly in the endoplasmic reticulum | Q33826597 | ||
| P433 | issue | 28 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus | Q808 |
| Zika virus | Q202864 | ||
| antibody | Q79460 | ||
| Dengue virus | Q476209 | ||
| Zika virus infection | Q27043680 | ||
| P5008 | on focus list of Wikimedia project | WikiProject Zika Corpus | Q54439832 |
| P304 | page(s) | 201607931 | |
| P577 | publication date | 2016-06-27 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus | |
| P478 | volume | 113 |
| Q30250988 | "Locked in a cage"-A case of dengue virus 4 encephalitis |
| Q89688806 | A Protein Epitope Targeted by the Antibody Response to Kawasaki Disease |
| Q38740798 | A Sensitive Method for Detecting Zika Virus Antigen in Patients' Whole-Blood Specimens as an Alternative Diagnostic Approach |
| Q54558545 | A Simple Flow Cytometry Based Assay to Determine In Vitro Antibody Dependent Enhancement of Dengue Virus Using Zika Virus Convalescent Serum. |
| Q89911673 | A Simple Method for the Design and Development of Flavivirus NS1 Recombinant Proteins Using an In Silico Approach |
| Q66679537 | A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III |
| Q58611960 | A comparison of Zika and dengue outbreaks using national surveillance data in the Dominican Republic |
| Q58769644 | A conceptual model for optimizing vaccine coverage to reduce vector-borne infections in the presence of antibody-dependent enhancement |
| Q92815825 | A high-throughput and multiplex microsphere immunoassay based on non-structural protein 1 can discriminate three flavivirus infections |
| Q28950443 | A human antibody against Zika virus crosslinks the E protein to prevent infection |
| Q33825684 | A human inferred germline antibody binds to an immunodominant epitope and neutralizes Zika virus |
| Q84957921 | A new class of broadly neutralizing antibodies that target the glycan loop of Zika virus envelope protein |
| Q38157419 | A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses |
| Q38158037 | A relevant in vitro human model for the study of Zika virus antibody-dependent enhancement. |
| Q61053666 | Advances in Diagnostic Methods for Zika Virus Infection |
| Q51336416 | Adverse outcomes of pregnancy-associated Zika virus infection. |
| Q60193818 | Amphiphilic block copolymer delivery of a DNA vaccine against Zika virus |
| Q47548142 | An evolutionary NS1 mutation enhances Zika virus evasion of host interferon induction |
| Q29352285 | An mRNA-based vaccine strategy against Zika |
| Q94511915 | An open source tool to infer epidemiological and immunological dynamics from serological data: Serosolver |
| Q28595141 | An unamplified RNA sensor for on-site screening of Zika virus disease in a limited resource setting |
| Q38158525 | An update on Zika virus infection |
| Q38157718 | Antibody-based assay discriminates Zika virus infection from other flaviviruses |
| Q37730661 | Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects |
| Q62485190 | Antigenic cross-reactivity between Zika and dengue viruses: is it time to develop a universal vaccine? |
| Q43047028 | Assessing the population at risk of Zika virus in Asia - is the emergency really over? |
| Q84957976 | Association of past dengue fever epidemics with the risk of Zika microcephaly at the population level in Brazil |
| Q59349637 | Basics of memory B-cell responses: lessons from and for the real world |
| Q55277816 | Biochemistry and Molecular Biology of Flaviviruses. |
| Q29365355 | Biologic Evidence Required for Zika Disease Enhancement by Dengue Antibodies |
| Q61053646 | CD4+ T cells promote humoral immunity and viral control during Zika virus infection |
| Q58744078 | CD4+T cells mediate protection against Zika associated severe disease in a mouse model of infection |
| Q54558491 | CE-BLAST makes it possible to compute antigenic similarity for newly emerging pathogens. |
| Q40043006 | Cellular and molecular mechanisms of viral infection in the human placenta. |
| Q61053643 | Challenges in diagnosing Zika-experiences from a reference laboratory n a non-endemic setting |
| Q30145645 | Characterization of Zika virus binding and enhancement potential of a large panel of flavivirus murine monoclonal antibodies |
| Q57464788 | Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus |
| Q41925407 | Circulation of DENV2 and DENV4 in Aedes aegypti (Diptera: Culicidae) mosquitoes from Praia, Santiago Island, Cabo Verde |
| Q61442843 | Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients: Prolonged RNA Detection in Whole Blood |
| Q47547831 | Co-circulation and simultaneous co-infection of dengue, chikungunya, and zika viruses in patients with febrile syndrome at the Colombian-Venezuelan border |
| Q59245668 | Combination of non-structural protein 1-based enzyme-linked immunosorbent assays can detect and distinguish various dengue virus and Zika virus infections |
| Q93031579 | Comparative specificity and sensitivity of NS1-based serological assays for the detection of flavivirus immune response |
| Q39416470 | Compensating for cross-reactions using avidity and computation in a suspension multiplex immunoassay for serotyping of Zika versus other flavivirus infections |
| Q60031649 | Comprehensive evaluation of differential serodiagnosis between Zika and dengue viral infection |
| Q90164445 | Computationally Designed Peptides for Zika Virus Detection: An Incremental Construction Approach |
| Q60031600 | Concomitant transmission of dengue, chikungunya and Zika viruses in Brazil: Clinical and epidemiological findings from surveillance for acute febrile illness |
| Q30250932 | Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope |
| Q56341683 | Critical role of CD4 T cells and IFNγ signaling in antibody-mediated resistance to Zika virus infection |
| Q28833082 | Cross reactivity of commercial anti-dengue immunoassays in patients with acute Zika virus infection |
| Q64257362 | Cross-Protection Against Four Serotypes of Dengue Virus in Mice Conferred by a Zika DNA Vaccine |
| Q90358753 | Cross-Reaction, Enhancement, and Neutralization Activity of Dengue Virus Antibodies against Zika Virus: A Study in the Mexican Population |
| Q58671999 | Cross-Reactive Dengue Virus Antibodies Augment Zika Virus Infection of Human Placental Macrophages |
| Q90345244 | Cross-Reactive Immunity Among Flaviviruses |
| Q56341981 | Cross-reactive Dengue virus-specific CD8 T cells protect against Zika virus during pregnancy |
| Q40047603 | Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections |
| Q59789593 | Cross-reactive dengue virus-derived monoclonal antibodies to Zika virus envelope protein: Panacea or Pandora's box? |
| Q98169775 | Current vector research challenges in the greater Mekong subregion for dengue, Malaria, and Other Vector-Borne Diseases: A report from a multisectoral workshop March 2019 |
| Q38157397 | DNA-immunisation with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and Yellow Fever virus infection. |
| Q58749402 | Deconvolution of pro- and antiviral genomic responses in Zika virus-infected and bystander macrophages |
| Q55084361 | Delayed and highly specific antibody response to nonstructural protein 1 (NS1) revealed during natural human ZIKV infection by NS1-based capture ELISA. |
| Q33798068 | Delineating antibody recognition against Zika virus during natural infection |
| Q61795493 | Dengue Virus Immunity Increases Zika Virus-Induced Damage during Pregnancy |
| Q28108975 | Dengue Virus-Specific Antibodies Enhance Brazilian Zika Virus Infection |
| Q38797690 | Dengue and West Nile Virus Transmission in Children and Adults in Coastal Kenya |
| Q66679191 | Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization |
| Q56343523 | Dengue immune sera enhance Zika virus infection in human peripheral blood monocytes through Fc gamma receptors |
| Q28353949 | Dengue virus antibodies enhance Zika virus infection |
| Q45324929 | Dengue virus-reactive CD8+ T cells mediate cross-protection against subsequent Zika virus challenge |
| Q40052993 | Detection, phenotyping and quantification of dengue virus-specific B cells using fluorescent probes |
| Q51336273 | Development and evaluation of a novel high-throughput image-based fluorescent neutralization test for detection of Zika virus infection. |
| Q47558158 | Development of Antibody Therapeutics against Flaviviruses |
| Q47558416 | Development of Zika Virus Serologic Testing Strategies in New York State |
| Q28736791 | Development of a high-throughput colorimetric Zika virus infection assay |
| Q56000964 | Development of a novel peptide aptamer-based immunoassay to detect Zika virus in serum and urine |
| Q47269331 | Development of envelope protein antigens to serologically differentiate Zika from dengue virus infection |
| Q50207356 | Development of vaccines against Zika virus |
| Q51336497 | Diagnosis of Zika Virus Infection by Peptide Array and Enzyme-Linked Immunosorbent Assay. |
| Q47558325 | Diagnosis of Zika Virus Infections: Challenges and Opportunities |
| Q55710677 | Diagnostic performance of commercial IgM and IgG enzyme-linked immunoassays (ELISAs) for diagnosis of Zika virus infection. |
| Q57284689 | Dicer-2 Regulates Resistance and Maintains Homeostasis against Zika Virus Infection in |
| Q61053661 | Differential Shedding and Antibody Kinetics of Zika and Chikungunya Viruses, Brazil |
| Q41918088 | Distinguishing secondary dengue virus infection from Zika virus infection with previous dengue by a combination of three simple serological tests |
| Q61053638 | Does prior dengue virus exposure worsen clinical outcomes of Zika virus infection? A systematic review, pooled analysis and lessons learned |
| Q92867102 | Efficient transplacental IgG transfer in women infected with Zika virus during pregnancy |
| Q56888687 | Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice |
| Q98578994 | Enhanced effect of modified Zika virus E antigen on the immunogenicity of DNA vaccine |
| Q29196526 | Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity |
| Q59245629 | Epidemiology of dengue and other arboviruses in a cohort of school children and their families in Yucatan, Mexico: Baseline and first year follow-up |
| Q28804198 | Evaluation of Possible Consequences of Zika Virus Infection in the Developing Nervous System |
| Q92644017 | Evaluation of novel rapid detection kits for dengue virus NS1 antigen in Dhaka, Bangladesh, in 2017 |
| Q36327441 | Exploring Human Antimicrobial Antibody Responses on a Single B Cell Level |
| Q56340482 | Exploring scenarios of chikungunya mitigation with a data-driven agent-based model of the 2014-2016 outbreak in Colombia |
| Q62485094 | Factors associated with the development of Congenital Zika Syndrome: a case-control study |
| Q47202386 | Fc gamma receptors are expressed in the developing rat brain and activate downstream signaling molecules upon cross-linking with immune complex |
| Q36236428 | Fcγ-receptor IIa-mediated Src Signaling Pathway Is Essential for the Antibody-Dependent Enhancement of Ebola Virus Infection |
| Q52421894 | Field-deployable viral diagnostics using CRISPR-Cas13. |
| Q57491430 | Flavivirus Receptors: Diversity, Identity, and Cell Entry |
| Q90798978 | Flavivirus infection-A review of immunopathogenesis, immunological response, and immunodiagnosis |
| Q51336433 | Gone or forgotten? The rise and fall of Zika virus. |
| Q92620042 | Heterologous viral protein interactions within licensed seasonal influenza virus vaccines |
| Q44843559 | High Zika Virus Seroprevalence in Salvador, Northeastern Brazil Limits the Potential for Further Outbreaks |
| Q90190740 | High specificity and sensitivity of Zika EDIII-based ELISA diagnosis highlighted by a large human reference panel |
| Q58571114 | High-throughput neutralization assay for multiple flaviviruses based on single-round infectious particles using dengue virus type 1 reporter replicon |
| Q56909500 | History of ZIKV Infections in India and Management of Disease Outbreaks |
| Q30235062 | Host-Virus Interaction of ZIKA Virus in Modulating Disease Pathogenesis |
| Q91675204 | Human Monoclonal Antibodies Potently Neutralize Zika Virus and Select for Escape Mutations on the Lateral Ridge of the Envelope Protein |
| Q66679208 | Human Polyclonal Antibodies Prevent Lethal Zika Virus Infection in Mice |
| Q66679189 | Human Schwann cells are susceptible to infection with Zika and yellow fever viruses, but not dengue virus |
| Q56000966 | Human Serum With High Neutralizing Antibody Titers Against Both Zika and Dengue Virus Shows Delayed In Vitro Antibody-Dependent Enhancement of Dengue Virus Infection |
| Q63248442 | Human antibody response to Zika targets type-specific quaternary structure epitopes |
| Q47558315 | Humoral Immune Responses Against Zika Virus Infection and the Importance of Preexisting Flavivirus Immunity |
| Q29994510 | Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology |
| Q28833079 | Hydrocephalus and arthrogryposis in an immunocompetent mouse model of ZIKA teratogeny: A developmental study |
| Q38157439 | Identification of putative unique immunogenic ZIKV and DENV1-4 peptides for diagnostic cellular based tests. |
| Q62485246 | Identification of relevant regions on structural and nonstructural proteins of for vaccine and diagnostic test development: an approach |
| Q28119651 | Identifying Candidate Targets of Immune Responses in Zika Virus Based on Homology to Epitopes in Other Flavivirus Species |
| Q33438726 | IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity |
| Q47551925 | Immune Response to Dengue and Zika |
| Q51336680 | Immune Responses to Dengue and Zika Viruses-Guidance for T Cell Vaccine Development. |
| Q26437328 | Immunogenic cross-talk between dengue and Zika viruses |
| Q62485447 | Impact of pre-existing dengue immunity on human antibody and memory B cell responses to Zika |
| Q38157106 | Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques |
| Q27928012 | Implication of vaccination against dengue for Zika outbreak |
| Q58758276 | Improved Immune Responses Against Zika Virus After Sequential Dengue and Zika Virus Infection in Humans |
| Q45324353 | In silico design of a Zika virus non-structural protein 5 aiming vaccine protection against zika and dengue in different human populations |
| Q54241842 | Incorporation of IgG Depletion in a Neutralization Assay Facilitates Differential Diagnosis of Zika and Dengue in Secondary Flavivirus Infection Cases. |
| Q66679581 | Inferring who-infected-whom-where in the 2016 Zika outbreak in Singapore-a spatio-temporal model |
| Q62485204 | Innate immune response in patients with acute Zika virus infection |
| Q41919129 | Innate, T and B Cell Responses in Acute Human Zika Patients |
| Q29051494 | Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection |
| Q66679510 | Large-scale analysis of B-cell epitopes of envelope: Implications for Zika vaccine and immunotherapeutic development |
| Q54241921 | Longitudinal Analysis of Antibody Cross-Neutralization Following Zika and Dengue Virus Infection in Asia and the Americas. |
| Q90167856 | Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine |
| Q59245659 | Maternally Acquired Zika Antibodies Enhance Dengue Disease Severity in Mice |
| Q56336242 | Mathematical modeling of within-host Zika virus dynamics |
| Q38787408 | Meeting Report: WHO consultation on considerations for regulatory expectations of Zika virus vaccines for use during an emergency |
| Q56361211 | Micro-droplet Digital Polymerase Chain Reaction and Real-Time Quantitative Polymerase Chain Reaction Technologies Provide Highly Sensitive and Accurate Detection of Zika Virus |
| Q54217627 | Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection. |
| Q45324805 | Multiplexed biomarker panels discriminate Zika and Dengue virus infection in humans |
| Q92028890 | NS1 DNA vaccination protects against Zika infection through T cell-mediated immunity in immunocompetent mice |
| Q26247567 | Navigating the Zika panic |
| Q57065009 | Neighborhood Violence Impacts Disease Control and Surveillance: Case Study of Cali, Colombia from 2014 to 2016 |
| Q41919737 | Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. |
| Q41924121 | Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques. |
| Q30145606 | No serological evidence for Zika virus infection and low specificity for anti-Zika virus ELISA in malaria positive individuals among pregnant women from Madagascar in 2010. |
| Q91887815 | Novel anti-flavivirus drugs targeting the nucleolar distribution of core protein |
| Q66678812 | Novel differential linear B-cell epitopes to identify Zika and dengue virus infections in patients |
| Q47558388 | Ontogeny of the B- and T-cell response in a primary Zika virus infection of a dengue-naïve individual during the 2016 outbreak in Miami, FL. |
| Q60487631 | Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region |
| Q47548101 | Passive immunotherapy of viral infections: 'super-antibodies' enter the fray |
| Q66679798 | Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes |
| Q60031660 | Potential inconsistencies in Zika surveillance data and our understanding of risk during pregnancy |
| Q61053973 | Pre-Existing Dengue Immunity Drives a DENV-Biased Plasmablast Response in ZIKV-Infected Patient |
| Q93004336 | Presence of Flavivirus Antibodies Does Not Lead to a Greater Number of Symptoms in a Small Cohort of Canadian Travelers Infected with Zika Virus |
| Q33715238 | Preventive and therapeutic challenges in combating Zika virus infection: are we getting any closer? |
| Q92612271 | Previous dengue or Zika virus exposure can drive to infection enhancement or neutralisation of other flaviviruses |
| Q90472263 | Primary and secondary dengue virus infections elicit similar memory B cell responses but breadth to other serotypes and cross-reactivity to Zika virus is higher in secondary dengue |
| Q41924182 | Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans |
| Q40037808 | Prior Exposure to Zika Virus Significantly Enhances Peak Dengue-2 Viremia in Rhesus Macaques |
| Q54221789 | Probing Molecular Insights into Zika Virus⁻Host Interactions. |
| Q50024775 | Prolonged Zika virus viremia in a patient with Guillain-Barré syndrome in Trinidad and Tobago. |
| Q99731978 | Protective and enhancing interactions among dengue viruses 1-4 and Zika virus |
| Q51336164 | Rapid response to an emerging infectious disease - Lessons learned from development of a synthetic DNA vaccine targeting Zika virus. |
| Q38158407 | Recent advances in understanding the adaptive immune response to Zika virus and the effect of previous flavivirus exposure |
| Q92471671 | Reciprocal immune enhancement of dengue and Zika virus infection in human skin |
| Q30145646 | Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico |
| Q39149955 | Reducing uncertainty about flavivirus infections |
| Q92622870 | Risk of Zika microcephaly correlates with features of maternal antibodies |
| Q33883729 | Risk of bias and confounding of observational studies of Zika virus infection: A scoping review of research protocols |
| Q101226405 | Risk of dengue virus infection according to serostatus in individuals from dengue endemic areas of Mexico |
| Q90148649 | Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies |
| Q58787712 | Salivary Detection of Dengue Virus NS1 Protein with a Label-Free Immunosensor for Early Dengue Diagnosis |
| Q56341577 | Sampling considerations for a potential Zika virus urosurvey in New York City |
| Q90733120 | Seeking Flavivirus Cross-Protective Immunity |
| Q90205634 | Serologic Tools and Strategies to Support Intervention Trials to Combat Zika Virus Infection and Disease |
| Q59353686 | Serological Cross Reactivity between Zika and Dengue Viruses in Experimentally Infected Monkeys |
| Q49820101 | Seroprevalence of Dengue and Chikungunya Virus Antibodies, French Polynesia, 2014-2015. |
| Q50318207 | Seroprevalence of dengue IgG antibodies in symptomatic and asymptomatic individuals three years after an outbreak in Zhejiang Province, China |
| Q47118600 | Shared IgG Infection Signatures vs. Hemorrhage-Restricted IgA Clusters in Human Dengue: A Phenotype of Differential Class-Switch via TGFβ1. |
| Q90159999 | Single cell immune profiling of dengue virus patients reveals intact immune responses to Zika virus with enrichment of innate immune signatures |
| Q61053717 | Small molecules targeting the flavivirus E protein with broad-spectrum activity and antiviral efficacy in vivo |
| Q43046666 | Specific detection of dengue and Zika virus antibodies using envelope proteins with mutations in the conserved fusion loop |
| Q54557941 | Strategies Towards Protease Inhibitors for Emerging Flaviviruses. |
| Q93162327 | Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody |
| Q61053963 | Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope |
| Q47555436 | Structural biology of Zika virus and other flaviviruses |
| Q47555900 | Sustained specific and cross-reactive T cell responses to Zika and Dengue viruses NS3 in West Africa |
| Q90382852 | Syncytiotrophoblast of Placentae from Women with Zika Virus Infection Has Altered Tight Junction Protein Expression and Increased Paracellular Permeability |
| Q56341655 | T Cell Responses to Nonstructural Protein 3 Distinguish Infections by Dengue and Zika Viruses |
| Q38156586 | T-cell Responses in Individuals Infected with Zika Virus and in Those Vaccinated Against Dengue Virus. |
| Q38848948 | Taking the Defensive: Immune Control of Zika Virus Infection |
| Q55464971 | Targeting vaccinations for the licensed dengue vaccine: Considerations for serosurvey design. |
| Q33681310 | Temperature-dependent folding allows stable dimerization of secretory and virus-associated E proteins of Dengue and Zika viruses in mammalian cells |
| Q41921294 | The African Zika virus MR-766 is more virulent and causes more severe brain damage than current Asian lineage and Dengue virus. |
| Q28804225 | The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis |
| Q59356038 | The Good, the Bad, and the Shocking: The Multiple Roles of Dengue Virus Nonstructural Protein 1 in Protection and Pathogenesis |
| Q61053970 | The distribution of important sero-complexes of flaviviruses in Malaysia |
| Q59069221 | The emergence of Zika virus and its new clinical syndromes |
| Q58569778 | The immune response against flaviviruses |
| Q51336389 | The immunology of Zika Virus. |
| Q91825917 | The inability of a dengue NS1 ELISA to detect Zika infections |
| Q63248438 | The possible role of cross-reactive dengue virus antibodies in Zika virus pathogenesis |
| Q92420536 | The role of co-infection and swarm dynamics in arbovirus transmission |
| Q90197061 | Time elapsed between Zika and dengue virus infections affects antibody and T cell responses |
| Q36267387 | Update on Zika Diagnostic Tests and WHO's Related Activities |
| Q56350169 | Use of Urea Wash ELISA to Distinguish Zika and Dengue Virus Infections |
| Q92492602 | Use of a Blockade-of-Binding ELISA and Microneutralization Assay to Evaluate Zika Virus Serostatus in Dengue-Endemic Areas |
| Q65054977 | Using Macaques to Address Critical Questions in Zika Virus Research. |
| Q29571224 | Vaccination strategies against Zika virus |
| Q41920081 | Viral Load and Cytokine Response Profile Does Not Support Antibody-Dependent Enhancement in Dengue-Primed Zika Virus-Infected Patients |
| Q47551884 | Viral and Antibody Kinetics, and Mosquito Infectivity of an Imported Case of Zika Fever Due to Asian Genotype (American Strain) in Singapore |
| Q60046445 | Viral-Induced Enhanced Disease Illness |
| Q28804195 | Vulnerability of primitive human placental trophoblast to Zika virus |
| Q38157725 | Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Challenges of a Dengue Vaccine |
| Q56337605 | Why is congenital Zika syndrome asymmetrically distributed among human populations? |
| Q28804230 | ZIKA Virus and Neuroscience: the Need for a Translational Collaboration |
| Q91730082 | Zika Vaccine Development: Current Status |
| Q54558232 | Zika Virus Exposure in an HIV-Infected Cohort in Ghana |
| Q92441397 | Zika Virus Infection in Pregnancy: Advanced Diagnostic Approaches in Dengue-Naive and Dengue-Experienced Pregnant Women and Possible Implication for Cross-Reactivity and Cross-Protection |
| Q90616810 | Zika Virus Infection, Reproductive Organ Targeting, and Semen Transmission in the Male Olive Baboon |
| Q78177348 | Zika Virus Outbreak on Curaçao and Bonaire, a Report Based on Laboratory Diagnostics Data. |
| Q28733400 | Zika Virus Pathogenesis and Tissue Tropism |
| Q28310404 | Zika Virus Seroprevalence, French Polynesia, 2014–2015 |
| Q58742686 | Zika Virus Vaccines: Challenges and Perspectives |
| Q27787384 | Zika Virus in Transplantation: Emerging Infection and Opportunities |
| Q92150862 | Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection |
| Q38969772 | Zika Virus: Immunity and Vaccine Development |
| Q60919470 | Zika Virus: Origins, Pathological Action, and Treatment Strategies |
| Q32183208 | Zika Virus: Recent Advances towards the Development of Vaccines and Therapeutics |
| Q30235853 | Zika Virus: Transmission, Detection, Control, and Prevention |
| Q55645060 | Zika convalescent macaques display delayed induction of anmanestic cross-neutralizing antibody responses after dengue infection. |
| Q38158442 | Zika enhancement: a reality check |
| Q29647477 | Zika puzzle in Brazil: peculiar conditions of viral introduction and dissemination - A Review |
| Q84957860 | Zika seroprevalence declines and neutralizing antibodies wane in adults following outbreaks in French Polynesia and Fiji |
| Q40055024 | Zika vaccine trials |
| Q38156674 | Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors. |
| Q51336553 | Zika virus and pregnancy in Brazil: What happened? |
| Q41918368 | Zika virus infection confers protection against West Nile virus challenge in mice |
| Q61795469 | Zika virus infection in Malaysia: an epidemiological, clinical and virological analysis |
| Q50020968 | Zika virus outbreak: a review of neurological complications, diagnosis, and treatment options. |
| Q33850577 | Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus |
| Q54558329 | Zika virus vaccines: immune response, current status, and future challenges. |
| Q26742229 | Zika virus — reigniting the TORCH |
| Q61795485 | Zika virus: Epidemiological surveillance of the Mexican Institute of Social Security |
| Q28278045 | Zika virus: from pathogenesis to disease control |
Search more.